阿托品联合双焦镜控制青少年轻中度近视疗效分析

Objective To evaluate the efficacy and safety of topical atropine and bifocal lens in slowing the progression of myopia and ocular axial elongation in children with slight to moderate myopia. Methods This trial included 62 children with slight to moderate myopia. They were all being treated in the Second Hospital of the Zhengzhou of Henan. Forty-two children were treated with 1% atropine ointment once daily before sleep for 1 year, and were demanded to wear bifocal lens at the same time. The other children were assigned to control group. Baseline and last assessments of refractive errors by cycloplegic autorefiaction and of axial length were done by ultrasound biometry. Intraocular pressure and corneal curvature were also recorded. The results were compared with data of control subjects. Results The visual acuity of 38 eyes (36.84%) in the treated group cutted down, compared with 80% in the control group. After 1 year, the mean progression of myopia and of axial elongation in the control group was -1.19±1.48D and 0.70± 0.63mm respectively. In the atropine-treated eyes, the mean progression of myopia was only±0.06± 0.79D and of axial elongation was 0.09± 0.19mm. Five children were forced to stop treatment because of photophobia and anaphylactic conjunctivitis. No other major adverse effects related to the treatment were noted. Conclusions 1% Atropine ointment and bifocal lens are safe and effective treatment for retarding myopic progression in slight to moderate myopia.This treatment is well tolerated by most children.

Atropine and bifcal lens in retarding myopia progression in children with slight to moderate myopia